|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 114.88 USD | +0.57% |
|
-2.69% | +16.31% |
| 07-14 | Barclays Adjusts Incyte Price Target to $134 From $117, Maintains Overweight Rating | MT |
| 07-13 | Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| INCYTE CORPORATION | Biopharmaceuticals | +0.57% | -2.69% | +16.31% | +64.16% | +43.83% | 22.95B |  | | |
- Stock Market
- Stocks
- INCY Stock
- Charts Incyte Corporation
- Comparison Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
